Companies collaborate to offer AI powered assessment of biological age and cardiovascular risk from retinal scans.
Longevity medicine platform Lifeforce and retinal imaging specialist Toku have joined forces in a partnership aimed at enabling earlier health insights and improving preventive care. The collaboration will see Lifeforce integrate Toku’s AI-powered retinal imaging technology, which allows routine eye exams to serve as a gateway for assessing biological aging and cardiovascular risk.
With thousands of eye exams taking place across the US each week, the partnership aims to scale preventive health screening and make proactive health optimization more accessible. By analyzing a single image of the retina, Toku’s system can generate real-time estimates of a person’s biological age and provide risk assessments for systemic health conditions. The company’s non-invasive approach leverages the retina as an accessible biomarker of vascular and metabolic health, drawing on subtle signals in retinal blood vessels and tissue to produce a personalized snapshot of a person’s health.
Lifeforce, which offers at-home biomarker testing, physician consultations, lifestyle coaching and evidence-based therapies, will integrate Toku’s first product, called BioAge, into its platform. BioAge is currently available in the US as a wellness product designed to increase awareness of aging by comparing biological and chronological age based on retinal biomarkers. Those who complete a BioAge scan will be linked to Lifeforce’s clinical and coaching network, where they can proactively address their aging and cardiovascular risks informed by the scan data.
“Seeing risk is only half the battle; acting on it is what changes lives,” said Lifeforce CEO Dugal Bain-Kim. “Toku delivers the earliest possible signal, and Lifeforce supplies the clinician guided programs that can slow aging, reduce cardiovascular risk, and extend healthspan.”
The partnership also leverages CLAiR, Toku’s AI-based retinal imaging platform that aims to deliver clinical-grade cardiovascular risk assessments. While still under development and not yet approved for clinical use, CLAiR has received Breakthrough Device designation from the FDA, and the company says it expects FDA approval in 2026.
“Partnering with Lifeforce ensures that our users are not only empowered with their health data but also supported by an elite, evidence-based longevity care team,” said Toku CEO Ehsan Vaghefi. “Together, we’re enabling a proactive and accessible approach to lifelong wellbeing.”
